Pharmaceutical Last week’s research focussed news saw positive results from Ascendis Pharma for its TransCon PTh in adult patients with hypoparathyroidism, and Roche with two-year data for its spinal atrophy drug Evrysdi. Also, Regeneron’s COVID-19 cocktail REGN-COV2, in an analysis of Phase I/II/III trials demonstrated reduced viral symptoms in non-hospital patients. On the deal-making front, Norway’s Vaccibody signed up on a collaboration with Roche subsidiary Genentech, potentially worth more than $700 million, for its neoantigen cancer vaccines, notably VB10.NEO. 4 October 2020